An Analysis of the DECISION Trial

December 20, 2013
Marcia S. Brose, MD, PhD

Marcia S. Brose, MD, PhD, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Clinical Pearls:

  • The DECISION trial was a placebo-controlled, randomized trial that tested the efficacy of sorafenib in patients with differentiated thyroid cancer that had progressed following radioactive iodine
  • These patients were randomized 1:1 to either sorafenib or placebo
  • The results showed that the progression-free survival in the sorafenib arm was significantly increased to 10.8 months compared to 5.8 months in the placebo arm
  • This data is statistically significant with a hazard ratio of .587 and aPvalue of less than .0001